Skip to content

Azapetine

CARDIOVASCULAR SYSTEM

Also known as: azapetine phosphate, ilidar, ilidar phosphate, peridil, Ro-2-3248

ATC C04AX30

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Azapetine is a drug catalogued in DrugCentral. DrugCentral lists 2 molecular targets, including Adra1b|Adra1d|Adra1a and Adra2b|Adra2c|Adra2a. Recorded indications include Peripheral vascular disease.

  • Molecular targets: Adra1b|Adra1d|Adra1a and Adra2b|Adra2c|Adra2a (2 listed in DrugCentral).
  • Indications: Peripheral vascular disease.
  • ATC code: C04AX30 (Other peripheral vasodilators).
  • Molecular formula: C17H17N; molecular weight 235.33 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Peripheral vascular disease

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Adrenergic receptor alpha-1Adra1b|Adra1d|Adra1aunknownIC50 6.69
Adrenergic receptor alpha-2Adra2b|Adra2c|Adra2aunknownIC50 5.89

ATC classification

ATC codeTherapeutic hierarchy
C04AX30CARDIOVASCULAR SYSTEM › PERIPHERAL VASODILATORS › PERIPHERAL VASODILATORS › Other peripheral vasodilators

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Azapetine is on its molecule page.

Molecular formulaC17H17N
Molecular weight235.33 g/mol
CAS number146-36-1
InChIKeyNYGHGTMKALXFIA-UHFFFAOYSA-N
PubChem CID8966
C=CCN1CC2=CC=CC=C2C2=C(C1)C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Azapetine used for?

DrugCentral lists the following indications for Azapetine: Peripheral vascular disease.

How does Azapetine work?

Its molecular targets in DrugCentral include Adra1b|Adra1d|Adra1a and Adra2b|Adra2c|Adra2a.

What is the chemical formula of Azapetine?

Azapetine has the molecular formula C17H17N and a molecular weight of 235.33 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval—
Agency—
Targets2
Indications1
FormulaC17H17N
DrugCentral ID265
Interactive profile